미국 · 보도자료 · Candel Therapeutics · 2026-10-01 12:05
폐암 병용 면역요법, 임상 2a상서 생존 기간 연장 입증
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of final phase 2a clinical trial results ( NCT04495153 ) of aglatimagene besadenovec (aglatimagene) plus v
Candel Therapeutics 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
